VEO™ Lateral Access & Interbody Fusion System
Seeing is Believing
The new VEO Lateral System brings clear and direct visualization to lateral fusion surgery. Through a combination of direct psoas visualization and unrestricted lateral fluoroscopic views, the VEO Lateral System offers complete visualization of the operative site. The VEO direct visualization approach was designed to help minimize iatrogenic trauma to the psoas muscle and the nerve plexus to help reduce the risk of post-operative complications.
Look Before You Leap
A radiolucent tubular retractor was designed to prevent soft tissue intrusion. It is the first of two retraction stages, providing direct visualization of the psoas muscle and associated nerves before dissection of the psoas. This critical intermediary step lets you augment neuromonitoring information with direct visualization and was designed to help avoid the nerves when dissecting through the psoas to the operative site.
Seeing the Possibilities
The VEO’s dual-blade, internal psoas retractor features controlled retraction in the anterior/posterior plane for a muscle-splitting and muscle-sparing approach. The retractor yields minimal muscle disruption while eliminating muscle creep, and offers excellent visualization of the operative site.
Evaluating Fusion at First Sight
The VEO Lateral System offers a comprehensive portfolio of interbody implants in both parallel and lordotic angles to match each patient’s anatomy. The VEO PEEK interbody implants contain 5 tantalum markers for precise fluoroscopic placement. The large center channel is readily visualized and easily evaluated during and after the procedure.
Watch the Performance
… Live
The VEO Lateral System provides a complete discectomy and endplate preparation instrument set. Designed specifically for a lateral approach, these instruments are dimensionally optimized for operative visualization and controlled surgical manipulations.
Indications For Use: The TranS1 lateral Interbody Fusion device is indicated for spinal fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). These patients should have had six months of non-operative treatment. The TranS1 Lateral Interbody Fusion Device is designed to be used with autogenous graft.
U.S. & Foreign Patents Applied For.
